ARX - Aroa Biosurgery

[Dona Ferentes]

quarterly out, 3 days of drops from $0.80 and now as low as $0.58

FINANCIAL HIGHLIGHTS
• Positive cash flows from operations of NZ$1.2 million during the quarter, reflecting the first quarter of positive cash flow since admission to the ASX in July 2020.
• Total cash on hand increased by NZ$0.3 million, ending the quarter with a strong cash balance of NZ$21.9 million.
• Strong cash receipts from customers of NZ$19.5 million during the quarter, in line with expectations.
• Net cash outflow from investing activities was NZ$0.8 million for the quarter, primarily reflecting routine capital expenditure.
• Full-year FY25 guidance (on a reported basis), is expected to be NZ$81-84 million total revenue (a 17-22% increase on FY24) and a normalised EBITDA profit of NZ$2-4 million.

OPERATIONAL HIGHLIGHTS
• The first peer reviewed study to emerge from the Company’s larger ‘MASTRR’ study was published in December. The real-world limb salvage study found Myriad Matrix™ and Myriad Morcells™ achieved tissue fill and coverage within 30 days with just one application and no complications. The findings of the study reinforce the efficacy of Myriad™ products in complex limb salvage procedures.
• AROA direct sales are now contributing 56% of the year-to-date sales mix, with Myriad expected to continue growing, becoming a larger part of the overall sales mix
• Regulatory approval received for Endoform™ and Myriad Matrix in Lebanon, Endoform in Vietnam, and Myriad in Saudi Arabia.

 

[Dona Ferentes]

ouch... clearly the punters were expecting more developments....will it repair itself?

 

[MartyC]

Now cashflow positive and moving towards profitability.
Looking for a short term bounce.

 

[Dona Ferentes]

Quarterly out on 29th of Feb
• Positive cash flows from operations of NZ$1.2 million during the quarter, reflecting the first quarter of positive cash flow since admission to the ASX in July 2020.
• Total cash on hand increased by NZ$0.3 million, ending the quarter with a strong cash balance of NZ$21.9 million.
• Strong cash receipts from customers of NZ$19.5 million during the quarter, in line with expectations.
• Net cash outflow from investing activities was NZ$0.8 million for the quarter, primarily reflecting routine capital expenditure.
• Full-year FY25 guidance (on a reported basis), is expected to be NZ$81-84 million total revenue (a 17-22% increase on FY24) and a normalised EBITDA profit of NZ$2-4 million.

YTD

 

[UMike]

Quite positive about this....
Surprised it is not performing better but then again not much makes sense to me recently.

 

[ROB67]

Seems to be a simple supply & demand issue, TOO MANY SELLERS , on my Brokerage account, i see all the buys & sells, some others don't ? as far as i know. There are too many people been trying/ sitting on a Sell price .55c +++, the stock hasn't traded above that barely past 2 months.
trading at about .44c, i'm looking at buying nearly 1/2 the shares soon at around .21c Average at this rate !!!! People just in to the seller's, it'll be at 1/2 the price at the high it reached .80c
It's all PSYCHOLOGY !!!

 

[UMike]

Not sure how you are going to do that?

I topped up and am hoping the tariff issue does not affect this stock too much,

 

[ROB67]

I Hope i don't, but i'm TRYING to support the stock ARX. I account for half the quantity of stocks on the BUY, 210K, as of today, an old trick I seen on other stocks, check out CCX, if you can see the full market depth, 6.2 million at a buy of .001 & .002 cents, i'm sure they aren't waiting for another GFC, even if, the stock would'nt sink that low i doubt.
Just making use, i hope of cash reserves.I will have exit those buy's eventually, the seller's do come in during the day,i've watched this stock, and others closely. But punters will push a stock down if less buyer's around, even if and especially when RSI is heading WELL South of 30% as a basic Metric.

 

[Dona Ferentes]

@mullokintyre

A singularly unsuccessful tip for the CY2025 competition. There has been nothing announced since late Jan, and the SP is falling away ever since. What will the next Quarterly update bring?

 

[UMike]

Hopefully it is lack of Invester interest rather than inside knowledge.

(My order got filled.... Not overly confident. )

 

[Dona Ferentes]

a steady retracement as per my cunning plan to stand out in the CY2025 tipping comp @mullokintyre

has been as low as $0.35 this year

.
Not much news; quarterly out on Tuesday 29th ..and that will be my May update?

 

[Dona Ferentes]

a steady retracement as per my cunning plan to stand out in the CY2025 tipping comp @mullokintyre

has been as low as $0.35 this year

@mullokintyre

get knocked down, don't get back up again

 

[Dona Ferentes]

$0.47

FY25 Results
• Total revenue of NZ$84.7 million (23% growth on FY24), exceeding guidance of $81-84 million.
• NZ$32.3 million in Myriad™ product revenue (38% growth on FY24).
• NZ$39.7 million in total OviTex™/ OviTex™ PRS product revenue (22% growth on FY24).
• Product gross margin of 86%.
• Normalised EBITDA profit of NZ$4.2 million (up from NZ$3.1 million normalised EBITDA loss in FY24), exceeding guidance of NZ$2 - 4 million.
• Achieved positive operating cash flow in H2 FY25, with cashflows from operations of NZ$2.3 million for H2 FY25.
• Strong cash balance of NZ$22.0 million with no debt.

FY26 Outlook
• Total revenue guidance of NZ$92-100 million (10 - 20% growth on FY25 on a constant currency basis), primarily driven by growth in Myriad sales, and continued investment in sales productivity. Myriad sales are expected to grow in excess of 25%. Sales to TELABio are conservatively estimated to grow at a more moderate pace.
• Normalised EBITDA of NZ$5-8 millioniv (19 - 90% growth on FY25), reflecting restrained clinical expenses and investment in new product development.

 

[Dona Ferentes]

This month's post for the yearly Comp @mullokintyre

Travelling sideways, no announcements of note

 

[Dona Ferentes]

This month's post for the yearly Comp @mullokintyre

Travelling sideways, no announcements of note

again, sideways is the case for this month.
Director options lapsed,
Quarterly due on Tuesday 29th

 

[Dona Ferentes]

This month's post for the yearly Comp @mullokintyre

another sideways month

FY26 Guidance ​

NZ$92 -100m Total Revenue
(YoY CC growth 10 – 20%), Myriad 25%+

NZ$5-8m - Normalised EBITDA

 

[UMike]

Hmmm @63c is actually up 10%

 

[Dona Ferentes]

This month's post for the yearly Comp @mullokintyre

SP showing a slow incremental stability - there have been no announcements in September to move it along